Interventions do not enhance medication persistence and compliance in patients with overactive bladder: a 24 weeks, randomised, open-label, multi-center trial

2015 ◽  
Vol 69 (11) ◽  
pp. 1309-1315 ◽  
Author(s):  
H. H. Sung ◽  
D. H. Han ◽  
T. H. Kim ◽  
Y.-S. Lee ◽  
H. N. Lee ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Medication Persistence ◽  
Open Label

Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study

2017 ◽  
Vol 197 (4) ◽  
pp. 1158-1163 ◽  
Author(s):  
Fannie Morin ◽  
Anne-Sophie Blais ◽  
Geneviève Nadeau ◽  
Katherine Moore ◽  
Lucie Genois ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Dual Therapy ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study

2007 ◽  
Vol 23 (11) ◽  
pp. 2697-2704 ◽  
Author(s):  
Simon Hill ◽  
Mostafa Elhilali ◽  
Richard J Millard ◽  
Peter L Dwyer ◽  
Karine Lheritier ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Extension Study ◽  
Open Label ◽  
Open Label Extension ◽  
Analysis Of Results

Overactive bladder medication: Persistence, drug switching, and reinitiation

2020 ◽  
Vol 39 (8) ◽  
pp. 2527-2534
Author(s):  
Takeshi Soda ◽  
Yu Tashiro ◽  
Shuhei Koike ◽  
Ryosuke Ikeuchi ◽  
Takuya Okada
Keyword(s):  
Overactive Bladder ◽  
Medication Persistence ◽  
Drug Switching

scholarly journals Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study)

2015 ◽  
Vol 116 (4) ◽  
pp. 612-622 ◽  
Author(s):  
Osamu Yamaguchi ◽  
Hidehiro Kakizaki ◽  
Yukio Homma ◽  
Yasuhiko Igawa ◽  
Masayuki Takeda ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Safety And Efficacy ◽  
Post Marketing
Sign in / Sign up

Export Citation Format

Share Document